Ultragenyx Pharmaceutical Inc. (RARE), a public biopharmaceutical company, has been making waves in the pharmaceutical industry with its commitment to developing innovative treatments for patients with rare and ultra-rare genetic diseases. Founded in 2010 and headquartered in Novato, California, Ultragenyx has been built on a foundation of determination and scientific brilliance.
The company's mission is clear: "Transform the treatment of rare and ultra-rare diseases by driving innovation and delivering value to patients" and over the past decade, Ultragenyx has made significant strides towards making this a reality. So far, the company has obtained approval for and launched three novel therapies, namely Crysvita (for X-linked hypophosphatemia and Tumor-Induced Osteomalacia), Mepsevii (for Mucopolysaccharidosis VII), and Dojolvi (for Long-Chain Fatty Acid Oxidation Disorders). These approvals mark important milestones for Ultragenyx, and more importantly, bring much needed hope and treatment options for patients living with these diseases.
In addition to these, Ultragenyx has built an extensive pipeline of promising drug candidates to address other devastating genetic diseases. It is known for applying its knowledge and unique infrastructure to manage the complexities of developing and delivering therapies to patients with rare genetic diseases. Ultragenyx is committed to patient centricity and maintains direct dialogues with patients and caregivers to understand their journey and challenges.
Ultragenyx's dedication to scientific innovation and patient welfare is reflected in its strategic collaboration with production partners and medical communities around the world. The company takes pride in its specialized teams, who strive to develop breakthrough therapies by pushing the boundaries of creativity and possibility.
Another notable achievement of Ultragenyx is its conscious effort to foster a culture of transparency, teamwork, courage, and relentless passion for creating the extraordinary. The company ardently promotes these values and has created a culture where employees can bring their best selves to work.
What elevates Ultragenyx in the pharmaceutical industry is not just the company's dedication to cultivating novel treatments for rare diseases, but also its commitment to operating sustainably and responsibly. With a keen eye for the future, this company is playing a significant role in transforming the face of the rare disease landscape, thereby bringing hope and improved quality of life to countless patients and families globally.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $34.58. The company recently surpassed quarterly earnings expectations, reporting an adjusted loss of $0.90 per share against an anticipated $1.22 loss, and revenues of $214 million, a 28.5% increase year-over-year. Despite mixed recent analyst actions, institutional investors hold a significant 97.67% of the company's shares.
Shares of Ultragenyx Pharmaceutical Inc. rose significantly after the FDA approved Fayuvi, its gene therapy for Sanfilippo syndrome Type A. Investment firm Sofinnova Investments, a large shareholder, had filed a Freedom of Information Act (FOIA) request with the FDA about Ultragenyx’s manufacturing compliance ahead of the approval decision. This action highlights how investment professionals use FOIA requests as a strategic tool to assess regulatory risks and market uncertainties surrounding drug approvals.
Ultragenyx has received FDA approval for its $4 million gene therapy designed to treat a rare brain and nervous system disorder. The one-time infusion therapy aims to correct the genetic cause of Sanfilippo syndrome, a condition affecting approximately one in every 70,000 births. This approval marks a significant milestone for the company in addressing rare genetic diseases.
The FDA has approved Ultragenyx's gene therapy Fayuvi for mucopolysaccharidosis type IIIA (MPS IIIA), a rare neurodegenerative disorder, marking the first treatment for the underlying disease. This approval follows a previous rejection due to manufacturing issues and provides a significant boost for Ultragenyx despite a recent late-stage clinical setback. Fayuvi has shown positive cognitive outcomes in young children with MPS IIIA, offering a new therapeutic option for affected families.
Ultragenyx Pharmaceutical has priced its new gene therapy, Fayuvi, at $3.95 million for the treatment of Sanfilippo syndrome Type A, a rare and fatal childhood neurological disease. The U.S. FDA approved the one-time treatment, which aims to clear toxic buildup in the brain and nervous system, following trials where treated children maintained or improved cognitive function. J.P. Morgan analysts project peak worldwide sales for Fayuvi to reach $200 million to $250 million.
Ultragenyx Pharmaceutical Inc. has received FDA approval for FAYUVI™ (rebisufligene etisparvovec-hopf), the first-ever gene therapy for Sanfilippo syndrome Type A (MPS IIIA). This approval marks a significant milestone for the devastating neurodegenerative disease, offering a potential treatment option where none existed before. Ultragenyx plans to make FAYUVI available through Qualified Treatment Centers, supported by its UltraCare® program to assist families with access.
Ultragenyx Pharmaceutical (RARE) stock hit a new 52-week low as investors await an FDA decision on UX111 for Sanfilippo syndrome type A. The stock's recent decline is also heavily influenced by the earlier failure of its Angelman syndrome drug trial, leading to significant market value loss. Despite these setbacks, the company recently secured FDA approval for Genglycos and aims for profitability by 2027.